MENOMUNE
Description
Menomune vaccine is a lyophilized Meningococcal polysaccharide vaccine, groups A,C,Y and W-135 combined, indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y and W-135. Menomune vaccine is approved for use in 2 years old and above. Menomune vaccine does not prevent N meningitidis serogroup B disease.
Immunization guideline:
Primary Vaccination: A single primary dose of 0.5 ml should be injected subcutaneously at 2 years of age.
For latest IAP updates see revised immunization schedule.
Additional information
manufacturer
Sanofi Pasteur
country-of-manufacture
USA
pharmaceutical-form
Liquid, Ready to Use
Vaccine Type
MeningococcalACYW-135 (conjugate vaccine)
package-size
1 Dose
route-of-administration
Intramuscular
preservative
Thiomersal
Contraindications
Do not administer to anyone with the history of severe allergic reaction to Menomune vaccine A, C, Y and W-135 or any component of vaccine.